IL251848A0 - Hetero-dimeric immunoglobulins targeting cd3/cd38 t cells and methods for their production - Google Patents

Hetero-dimeric immunoglobulins targeting cd3/cd38 t cells and methods for their production

Info

Publication number
IL251848A0
IL251848A0 IL251848A IL25184817A IL251848A0 IL 251848 A0 IL251848 A0 IL 251848A0 IL 251848 A IL251848 A IL 251848A IL 25184817 A IL25184817 A IL 25184817A IL 251848 A0 IL251848 A0 IL 251848A0
Authority
IL
Israel
Prior art keywords
production
methods
dimeric immunoglobulins
cell retargeting
hetero
Prior art date
Application number
IL251848A
Other languages
English (en)
Hebrew (he)
Original Assignee
Glenmark Pharmaceuticals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2014/073738 external-priority patent/WO2015063339A1/en
Application filed by Glenmark Pharmaceuticals Sa filed Critical Glenmark Pharmaceuticals Sa
Publication of IL251848A0 publication Critical patent/IL251848A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL251848A 2014-11-04 2017-04-23 Hetero-dimeric immunoglobulins targeting cd3/cd38 t cells and methods for their production IL251848A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/EP2014/073738 WO2015063339A1 (en) 2013-11-04 2014-11-04 Production of t cell retargeting hetero-dimeric immunoglobulins
EP15167034 2015-05-08
PCT/EP2015/075628 WO2016071355A1 (en) 2014-11-04 2015-11-03 Cd3/cd38 t cell retargeting hetero-dimeric immunoglobulins and methods of their production

Publications (1)

Publication Number Publication Date
IL251848A0 true IL251848A0 (en) 2017-06-29

Family

ID=53059011

Family Applications (1)

Application Number Title Priority Date Filing Date
IL251848A IL251848A0 (en) 2014-11-04 2017-04-23 Hetero-dimeric immunoglobulins targeting cd3/cd38 t cells and methods for their production

Country Status (20)

Country Link
EP (1) EP3215541A1 (ja)
JP (3) JP2018501297A (ja)
KR (1) KR20170078831A (ja)
CN (1) CN107207596A (ja)
AU (1) AU2015341884B2 (ja)
BR (1) BR112017009263A2 (ja)
CA (1) CA2965745C (ja)
CL (1) CL2017001090A1 (ja)
CO (1) CO2017005240A2 (ja)
EA (1) EA039658B1 (ja)
HK (1) HK1244014A1 (ja)
IL (1) IL251848A0 (ja)
MA (1) MA40894A (ja)
MX (1) MX2017005814A (ja)
MY (1) MY186929A (ja)
NZ (1) NZ732019A (ja)
PE (1) PE20171041A1 (ja)
PH (1) PH12017500819A1 (ja)
SG (1) SG11201703313SA (ja)
WO (1) WO2016071355A1 (ja)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11053316B2 (en) 2013-01-14 2021-07-06 Xencor, Inc. Optimized antibody variable regions
US10738132B2 (en) 2013-01-14 2020-08-11 Xencor, Inc. Heterodimeric proteins
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
EP3024851B1 (en) 2013-07-25 2018-05-09 CytomX Therapeutics, Inc. Multispecific antibodies, multispecific activatable antibodies and methods of using the same
SG11201603244VA (en) 2013-11-04 2016-05-30 Glenmark Pharmaceuticals Sa Production of t cell retargeting hetero-dimeric immunoglobulins
BR112016022385A2 (pt) 2014-03-28 2018-06-19 Xencor, Inc anticorpos específicos que se ligam a cd38 e cd3
CN107108738A (zh) * 2014-07-25 2017-08-29 西托姆克斯治疗公司 抗cd3抗体、可活化抗cd3抗体、多特异性抗cd3抗体、多特异性可活化抗cd3抗体及其使用方法
US11773166B2 (en) 2014-11-04 2023-10-03 Ichnos Sciences SA CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production
CN110894240B (zh) 2014-11-26 2022-04-15 森科股份有限公司 结合cd3和肿瘤抗原的异二聚体抗体
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
AU2015353416C1 (en) 2014-11-26 2022-01-27 Xencor, Inc. Heterodimeric antibodies that bind CD3 and CD38
TWI796283B (zh) 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Ｍｓｌｎ及ｃｄ３抗體構築體
TWI829617B (zh) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Ｆｌｔ３及ｃｄ３抗體構築體
JP7058219B2 (ja) 2015-12-07 2022-04-21 ゼンコア インコーポレイテッド Ｃｄ３及びｐｓｍａに結合するヘテロ二量体抗体
EA039859B1 (ru) 2016-02-03 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
CA3026151A1 (en) 2016-06-14 2017-12-21 Xencor, Inc. Bispecific checkpoint inhibitor antibodies
EP3475304B1 (en) 2016-06-28 2022-03-23 Xencor, Inc. Heterodimeric antibodies that bind somatostatin receptor 2
AU2018259039A1 (en) * 2017-04-24 2019-11-07 Ichnos Sciences SA T cell redirecting bispecific antibodies for the treatment of EGFR positive cancers
WO2018224441A1 (en) * 2017-06-05 2018-12-13 Numab Innovation Ag Novel anti-cd3 antibodies
AU2018280681A1 (en) 2017-06-05 2019-12-05 Numab Therapeutics AG Novel anti-CD3 antibodies
US20230103584A1 (en) * 2017-06-08 2023-04-06 Black Belt Therapeutics Limited Cd38 modulating antibody agents
WO2018224682A1 (en) 2017-06-08 2018-12-13 Tusk Therapeutics Ltd Cd38 modulating antibody
BR112020002636A2 (pt) * 2017-08-10 2020-07-28 Grifols Diagnostic Solutions Inc. composições, métodos e/ou kits que compreendem um domínio extracelular recombinante de cd38 humano
SG11202000484TA (en) 2017-08-16 2020-02-27 Black Belt Therapeutics Ltd Cd38 antibody
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
US11542338B2 (en) 2017-08-16 2023-01-03 Black Belt Therapeutics Limited CD38 modulating antibody
JP7438106B2 (ja) 2017-10-14 2024-02-26 シートムエックス セラピューティクス，インコーポレイテッド 抗体、活性化可能抗体、二重特異性抗体、および二重特異性活性化可能抗体ならびにその使用方法
US20220034899A1 (en) * 2018-09-25 2022-02-03 Ichnos Sciences S.A. Antibody quantification in biological samples
KR102353568B1 (ko) * 2018-11-14 2022-01-20 주식회사 헬릭스미스 안정성이 향상된 항 c-Met 항체 또는 그의 항원 결합 단편
AU2020211728A1 (en) * 2019-01-23 2021-08-12 Encefa CD31 competitors and uses thereof
US20220177582A1 (en) * 2019-03-13 2022-06-09 Ichnos Sciences SA Non-consensus glycosylation of bispecific antibodies
BR112021023026A2 (pt) * 2019-05-23 2022-01-04 Velosbio Inc Moléculas de ligação biespecíficas anti-ror1/anti-cd3
JPWO2020250940A1 (ja) * 2019-06-11 2020-12-17
CN110551222B (zh) * 2019-08-27 2023-06-06 重庆市畜牧科学院 一种新型双功能抗体及其用途
JP2022550832A (ja) * 2019-09-30 2022-12-05 和▲ハク▼医▲薬▼（▲蘇▼州）有限公司 Ｃｄ３を標的とする抗体、二重特異性抗体及びその使用
CN113493519B (zh) * 2020-03-19 2022-12-27 浙江道尔生物科技有限公司 一种半衰期显著延长的治疗眼部血管新生疾病的融合蛋白
JP2023523584A (ja) * 2020-04-24 2023-06-06 メモリアル スローン ケタリング キャンサー センター 抗ｃｄ３抗体及びその使用
WO2021231976A1 (en) 2020-05-14 2021-11-18 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
CA3180690A1 (en) * 2020-06-17 2021-12-23 Ahmed Mahiuddin Cd38 antibodies for treatment of human diseases
JP2023538891A (ja) 2020-08-19 2023-09-12 ゼンコア インコーポレイテッド 抗ｃｄ２８組成物
KR20230154311A (ko) 2021-03-10 2023-11-07 젠코어 인코포레이티드 Cd3 및 gpc3에 결합하는 이종이량체 항체

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2541489T3 (es) * 2004-02-06 2015-07-21 Morphosys Ag Anticuerpos humanos anti-CD38 y usos para ellos
CN107033243B (zh) * 2005-03-23 2020-12-15 根马布股份公司 用于治疗多发性骨髓瘤的cd38抗体
EP1945671A2 (en) * 2005-10-12 2008-07-23 MorphoSys AG Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human cd38
EP1914242A1 (en) * 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
EP3916011A1 (en) * 2009-06-26 2021-12-01 Regeneron Pharmaceuticals, Inc. Readily isolated bispecific antibodies with native immunoglobulin format
CN102770537A (zh) * 2009-12-25 2012-11-07 中外制药株式会社 用于纯化多肽多聚体的多肽的修饰方法
JP6093696B2 (ja) * 2010-06-09 2017-03-08 ゲンマブ エー／エス ヒトｃｄ３８に対する抗体
JOP20210044A1 (ar) * 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
CN107840894A (zh) * 2011-03-25 2018-03-27 格兰马克药品股份有限公司 异二聚体免疫球蛋白
CA2886036A1 (en) * 2012-09-25 2014-04-03 Glenmark Pharmaceuticals S.A. Purification of hetero-dimeric immunoglobulins
WO2014068114A1 (en) * 2012-11-05 2014-05-08 Morphosys Ag Radiolabelled antibody and uses thereof
SG11201603244VA (en) * 2013-11-04 2016-05-30 Glenmark Pharmaceuticals Sa Production of t cell retargeting hetero-dimeric immunoglobulins

Also Published As

Publication number Publication date
SG11201703313SA (en) 2017-05-30
JP2018501297A (ja) 2018-01-18
KR20170078831A (ko) 2017-07-07
AU2015341884B2 (en) 2020-09-17
PE20171041A1 (es) 2017-07-19
HK1244014A1 (zh) 2018-07-27
CO2017005240A2 (es) 2017-10-31
MY186929A (en) 2021-08-26
BR112017009263A2 (pt) 2018-01-30
PH12017500819A1 (en) 2017-10-02
WO2016071355A1 (en) 2016-05-12
EA201790961A1 (ru) 2017-10-31
CN107207596A (zh) 2017-09-26
EA039658B1 (ru) 2022-02-22
JP2019214582A (ja) 2019-12-19
CL2017001090A1 (es) 2018-01-05
MX2017005814A (es) 2017-08-02
EP3215541A1 (en) 2017-09-13
JP7403505B2 (ja) 2023-12-22
AU2015341884A1 (en) 2017-06-08
NZ732019A (en) 2022-07-29
JP2021184722A (ja) 2021-12-09
MA40894A (fr) 2017-09-12
CA2965745C (en) 2023-12-05
CA2965745A1 (en) 2016-05-12

Similar Documents

Publication Publication Date Title
HK1244014A1 (zh) Cd3/cd38 t細胞重靶向異源二聚體免疫球蛋白及其生產方法
IL286835A (en) Bispecific tetravalent antibodies and methods for their preparation and use
HK1252413A1 (zh) 培養阿克曼氏菌的方法
IL253149A0 (en) Methods for preparing cells expressing a chimeric receptor antigen
ZA201603433B (en) Production of t cell retargeting hetero-dimeric immunoglobulins
IL248007A0 (en) Bispecific antibodies that bind to cd38 and cd3
HK1251969A1 (zh) 抗her2抗體和使用方法
IL257411A (en) Improved production of immunoglobulins
HK1251580B (zh) 製造膜聯蛋白v的方法
ZA201700525B (en) Method of synthetic fuel gas production
IL248697A0 (en) Methods for purifying antibodies
IL250451A0 (en) Anti-vasa antibodies, and methods for their preparation and use
HUE063273T2 (hu) Heteromultimer fehérjék elõállítása emlõssejtek felhasználásával
GB201608060D0 (en) Method of culturing T cells
IL252712A0 (en) Method for protein production
GB2522716B (en) Method of manufacture
GB201411430D0 (en) Method of producing metallic tanralum
SG11201609269TA (en) Method of culturing cells
PT3194599T (pt) Método para produção de células modificadas que expressam hox e células modificadas obtidas pelo método